Axsome Therapeutics: The Biotech Star That's Just Getting Started
With a blockbuster portfolio and a pipeline brimming with potential, Axsome Therapeutics is proving its five-year market surge may be only the beginning. Analysts point to label expansions and untapped markets as key drivers for the next phase of growth.